College of Nursing, University of Utah, Salt Lake City, UT.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
JCO Clin Cancer Inform. 2024 Jul;8:e2300243. doi: 10.1200/CCI.23.00243.
People with cancer experience poorly controlled symptoms that persist between treatment visits. Automated digital technology can remotely monitor and facilitate symptom management at home. Essential to digital interventions is patient engagement, user satisfaction, and intervention benefits that are distributed across patient populations so as not to perpetuate inequities. We evaluated Symptom Care at Home (SCH), an automated digital platform, to determine patient engagement, satisfaction, and whether intervention subgroups gained similar symptom reduction benefits.
358 patients with cancer receiving a course of chemotherapy were randomly assigned to SCH or usual care (UC). Both groups reported daily on 11 symptoms and completed the SF36 (Short Form Health Survey) monthly. SCH participants received immediate automated self-care coaching on reported symptoms. As needed, nurse practitioners followed up for poorly controlled symptoms.
The average participant was White (83%), female (75%), and urban-dwelling (78.6%). Daily call adherence was 90% of expected days. Participants reported high user satisfaction. SCH participants had lower symptom burden than UC in all subgroups: age, sex, race, income, residence type, diagnosis, and stage (all < .001 effect size 0.33-0.65), except for stages I and II cancers. Non-White and lower-income SCH participants gained a higher magnitude of symptom reduction than White participants and higher-income participants. Additionally, SCH men gained higher SF36 mental health (MH) benefit. There were no differences on other SF36 indices.
Participants were highly satisfied and consistently engaged the SCH platform. SCH men gained large MH improvements, perhaps from increased comfort in sharing concerns through automated interactions. Although all intervention subgroups benefited, non-White participants and those with lower income gained higher symptom reduction benefit, suggesting that systematic care through digital tools can overcome existing disparities in symptom care outcomes.
癌症患者在治疗期间会经历控制不佳且持续存在的症状。自动化数字技术可以远程监测并在家中促进症状管理。数字干预的关键是患者参与度、用户满意度以及干预效益在患者群体中的分布,以避免不平等现象的持续存在。我们评估了 Symptom Care at Home(SCH),这是一个自动化的数字平台,以确定患者的参与度、满意度,以及干预亚组是否获得了类似的症状缓解益处。
358 名接受化疗疗程的癌症患者被随机分配到 SCH 或常规护理(UC)组。两组均每天报告 11 种症状,并每月完成 SF36(Short Form Health Survey)调查。SCH 组的参与者会收到针对报告症状的即时自动化自我护理指导。如有需要,护士从业者会跟进控制不佳的症状。
平均参与者为白人(83%)、女性(75%)和城市居民(78.6%)。每日电话依从率为预期天数的 90%。参与者报告了高度的用户满意度。在所有亚组中,SCH 组的症状负担均低于 UC 组:年龄、性别、种族、收入、居住类型、诊断和分期(所有 P<0.001,效应大小 0.33-0.65),除了 I 期和 II 期癌症。非白人参与者和低收入参与者比白人参与者和高收入参与者获得更高的症状缓解幅度。此外,SCH 男性在心理健康(MH)方面获得了更高的 SF36 收益。其他 SF36 指数没有差异。
参与者对 SCH 平台非常满意且始终保持参与度。SCH 男性在 MH 方面获得了显著的改善,这可能是由于通过自动化交互更愿意分享问题。尽管所有干预亚组都受益,但非白人参与者和收入较低的参与者获得了更高的症状缓解益处,这表明通过数字工具进行系统护理可以克服症状护理结果方面现有的差异。